Leila Zareian Baghdadabad
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Leila Zareian Baghdadabad has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
- Seyed Mohammad Kazem Aghamir
Urology Research Center, Tehran University of Medical Sciences, Tehran, Iran
3 shared publications - Abdolreza Mohammadi
Urology Research Center, Tehran University of Medical Sciences, Tehran, Iran
2 shared publications - Rahil Mashhadi
Urology Research Center, Tehran University of Medical Sciences, Tehran, Iran, tums.ac.ir
2 shared publications - Seyed Reza Yahyazadeh
Department of Urology, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran
2 shared publications - Akram Mirzaei
Urology Research Center Tehran University of Medical Sciences Tehran Iran
1 shared publication - Ali Tavoosian
Urology Research Center, Tehran University of Medical Sciences, Tehran, Iran, tums.ac.ir
1 shared publication
Latest Publications
- Open Access
- 10 March 2026
- Published by MDPI AG in Pharmaceutics
- Vol. 18 (3) , 338
Improved Anticancer Properties of Silver Nanoparticles by Albumin Coating in Prostate Cancer Cell Lines: An In Vitro Study
Background: Silver nanoparticles (AgNPs) trigger apoptosis in cancer cells, while albumin nanoparticles enable effective drug delivery. This study compares the antitumor and cytotoxic effects of albumin-coated AgNPs (AgNPs-Alb) versus AgNPs on human prostate cancer cell lines. Method: AgNPs-Alb were synthesized and tested against PC3 and LNCaP prostate cancer cell lines. Characterization via Transmission Electron Microscopy (TEM), Dynamic Light Scattering (DLS), and Ultraviolet-Visible (UV-Vis) spectroscopy confirmed their properties. IC50 values were determined using MTT assay, with apoptosis assessed by Annexin-V/PI staining. DNA cell cycle was analyzed by PI staining. Migration, proliferation, and nuclear morphology were evaluated through scratch-wound, colony-forming, and Hoechst staining assays. Gene expression of Snail, E-cadherin, VEGF-C, VEGF-A, Bcl2, Bax, and P53 was analyzed using real-time PCR. Results: The IC50 values for AgNPs and AgNPs-Alb were 48 μM and 32 μM in PC3 cells, and 110 μM and 95 μM in LNCaP cells, respectively. AgNPs-Alb significantly inhibited PC3 cell migration compared to AgNPs (p < 0.001) and Bicalutamide (p < 0.0001). In both cell lines, AgNPs-Alb significantly reduced colony formation compared to AgNPs and Bicalutamide (p < 0.05). Flow cytometry revealed a higher percentage of apoptotic cells in PC3 with AgNPs-Alb treatment compared to AgNPs and Bicalutamide. In LNCaP cells, AgNPs-Alb induced a significantly higher percentage of Sub-G1 cells. AgNPs-Alb treatment caused greater mRNA suppression of VEGF-A and a higher Bax/Bcl2 ratio in PC3 and LNCaP cells (p < 0.05). Additionally, a significant increase in P53 and E-cadherin, alongside a decrease in VEGF-C expression in LnCAP cells, was observed (p < 0.05). Conclusions: This study suggests that AgNPs-Alb have stronger anticancer and cytotoxic effects compared to AgNPs alone against PCa cell lines and higher effects were observed on PC3 cells compared to LnCAP cells.
- 10 March 2026
- Published by MDPI AG in Pharmaceutics
- Vol. 18 (3) , 338
Open AccessImproved Anticancer Properties of Silver Nanoparticles by Albumin Coating in Prostate Cancer Cell Lines: An In Vitro Study
Background: Silver nanoparticles (AgNPs) trigger apoptosis in cancer cells, while albumin nanoparticles enable effective drug delivery. This study compares the antitumor and cytotoxic effects of albumin-coated AgNPs (AgNPs-Alb) versus AgNPs on human prostate cancer cell lines. Method: AgNPs-Alb were synthesized and tested against PC3 and LNCaP prostate cancer cell lines. Characterization via Transmission Electron Microscopy (TEM), Dynamic Light Scattering (DLS), and Ultraviolet-Visible (UV-Vis) spectroscopy confirmed their properties. IC50 values were determined using MTT assay, with apoptosis assessed by Annexin-V/PI staining. DNA cell cycle was analyzed by PI staining. Migration, proliferation, and nuclear morphology were evaluated through scratch-wound, colony-forming, and Hoechst staining assays. Gene expression of Snail, E-cadherin, VEGF-C, VEGF-A, Bcl2, Bax, and P53 was analyzed using real-time PCR. Results: The IC50 values for AgNPs and AgNPs-Alb were 48 μM and 32 μM in PC3 cells, and 110 μM and 95 μM in LNCaP cells, respectively. AgNPs-Alb significantly inhibited PC3 cell migration compared to AgNPs (p < 0.001) and Bicalutamide (p < 0.0001). In both cell lines, AgNPs-Alb significantly reduced colony formation compared to AgNPs and Bicalutamide (p < 0.05). Flow cytometry revealed a higher percentage of apoptotic cells in PC3 with AgNPs-Alb treatment compared to AgNPs and Bicalutamide. In LNCaP cells, AgNPs-Alb induced a significantly higher percentage of Sub-G1 cells. AgNPs-Alb treatment caused greater mRNA suppression of VEGF-A and a higher Bax/Bcl2 ratio in PC3 and LNCaP cells (p < 0.05). Additionally, a significant increase in P53 and E-cadherin, alongside a decrease in VEGF-C expression in LnCAP cells, was observed (p < 0.05). Conclusions: This study suggests that AgNPs-Alb have stronger anticancer and cytotoxic effects compared to AgNPs alone against PCa cell lines and higher effects were observed on PC3 cells compared to LnCAP cells.
- Open Access
- 1 January 2025
- Published by XMLink in Clinical and Experimental Vaccine Research
- Vol. 14 (1) , 44-50
Impact of COVID-19 vaccination on lower urinary tract (LUTS) in benign prostatic hyperplasia (BPH) patients
Shamshirgaran A, et al. Clin Exp Vaccine Res. 2025 Jan;14(1):44-50. https://doi.org/10.7774/cevr.2025.14.e2
- 1 January 2025
- Published by XMLink in Clinical and Experimental Vaccine Research
- Vol. 14 (1) , 44-50
Open AccessImpact of COVID-19 vaccination on lower urinary tract (LUTS) in benign prostatic hyperplasia (BPH) patients
Shamshirgaran A, et al. Clin Exp Vaccine Res. 2025 Jan;14(1):44-50. https://doi.org/10.7774/cevr.2025.14.e2
- 1 May 2023
- Published by Maad Rayan Publishing Company
- Vol. 20 (3) , 136-143
Does the Prone Position During the Shockwave Lithotripsy of Kidney Stones Improve the Stone-Free Rate? Results from a Randomized Clinical Trial
Objective: This study aimed to evaluate the impact of the skin-to-stone distance in the supine and prone positions on the outcome of shockwave lithotripsy of kidney stones.Methods: In a prospective randomized clinical trial study, 81 patients that candidates for shockwave lithotripsy (SWL) of kidney stones were randomly divided into two groups to perform SWL in the prone position (40 patients) or conventional supine position (41 patients). Demographic data, stone characteristics, skin-to-stone distances (SSD) in CT, SSD during SWL with an ultrasound probe in prone and supine positions, total shock wave rate, total energy (kilovolt), visual analog scale (VAS), complications (Clavien-Dindo scale system), and SWL success rate evaluated in two intervention and control groups. All statistical analysis was performed by independent T-test, Chi-Square test, Fisher exact test, paired T-test, and SPSS 22.0 software for windows.Results: There were no significant differences between demographic characteristics, SWL sessions, the median number of SWLs, the median SWL time, median total energy, VAS, and complications in the two groups. The SFR was numerically higher in the prone SWL group than in the supine SWL group (80% vs. 73.2%) but was not significantly different (P = 0.468). Also, the inline ultrasound (US) measuring of the SSD in the prone position was significantly different from US SSD measures in the supine position in the two groups (Ps = 0.001 and 0.024). The mean SSD was lower in the US measurement during the SWL process that measured in supine and prone position than the CT measurement (73.5 vs. 101.1), which means the routine SSD measured by CT scan is higher than SSD in the US probe measurement during SWL.Conclusion: The prone position SWL modification could be effective in obese patients with a BMI of more than 30 and increase the stone-free rate (P=0.039) with a similar safety profile and comparable VAS score. It seems the SSD measured by the ultrasound is a more accurate dynamic measurement during the SWL and needs to define the SSD according to the SSD calculation by the US probe of the therapy head. SFR was numerically higher in the prone compared with the supine treatment groups
- 1 May 2023
- Published by Maad Rayan Publishing Company
- Vol. 20 (3) , 136-143
Does the Prone Position During the Shockwave Lithotripsy of Kidney Stones Improve the Stone-Free Rate? Results from a Randomized Clinical Trial
Objective: This study aimed to evaluate the impact of the skin-to-stone distance in the supine and prone positions on the outcome of shockwave lithotripsy of kidney stones.Methods: In a prospective randomized clinical trial study, 81 patients that candidates for shockwave lithotripsy (SWL) of kidney stones were randomly divided into two groups to perform SWL in the prone position (40 patients) or conventional supine position (41 patients). Demographic data, stone characteristics, skin-to-stone distances (SSD) in CT, SSD during SWL with an ultrasound probe in prone and supine positions, total shock wave rate, total energy (kilovolt), visual analog scale (VAS), complications (Clavien-Dindo scale system), and SWL success rate evaluated in two intervention and control groups. All statistical analysis was performed by independent T-test, Chi-Square test, Fisher exact test, paired T-test, and SPSS 22.0 software for windows.Results: There were no significant differences between demographic characteristics, SWL sessions, the median number of SWLs, the median SWL time, median total energy, VAS, and complications in the two groups. The SFR was numerically higher in the prone SWL group than in the supine SWL group (80% vs. 73.2%) but was not significantly different (P = 0.468). Also, the inline ultrasound (US) measuring of the SSD in the prone position was significantly different from US SSD measures in the supine position in the two groups (Ps = 0.001 and 0.024). The mean SSD was lower in the US measurement during the SWL process that measured in supine and prone position than the CT measurement (73.5 vs. 101.1), which means the routine SSD measured by CT scan is higher than SSD in the US probe measurement during SWL.Conclusion: The prone position SWL modification could be effective in obese patients with a BMI of more than 30 and increase the stone-free rate (P=0.039) with a similar safety profile and comparable VAS score. It seems the SSD measured by the ultrasound is a more accurate dynamic measurement during the SWL and needs to define the SSD according to the SSD calculation by the US probe of the therapy head. SFR was numerically higher in the prone compared with the supine treatment groups
- Open Access
- 8 June 2022
- Published by Hindawi Limited in Prostate Cancer
- Vol. 2022, 1-10
Diagnostic Accuracy of Predictive Models in Prostate Cancer: A Systematic Review and Meta-Analysis
Aim. Accurate diagnosis of prostate cancer (PCa) has a fundamental role in clinical and patient care. Recent advances in diagnostic testing and marker lead to standardized interpretation and increased prescription by clinicians to improve the detection of clinically significant PCa and select patients who strictly require targeted biopsies. Methods. In this study, we present a systematic review of the overall diagnostic accuracy of each testing panel regarding the panel details. In this meta-analysis, using a structured search, Web of Science and PubMed databases were searched up to 23 September 2019 with no restrictions and filters. The studys outcome was the AUC and 95 confidence interval of prediction models. This index was reported as an overall and based on the WHO region and models with/without MRI. Results. The thirteen final articles included 25,691 people. The overall AUC and 95 CI in thirteen studies were 0.78 and 95 CI: 0.730.82. The weighted average AUC in the countries of the Americas region was 0.73 (95 CI: 0.700.75), and in European countries, it was 0.80 (95 CI: 0.720.88). In four studies with MRI, the average weighted AUC was 0.88 (95 CI: 0.860.90), while in other articles where MRI was not a parameter in the diagnostic model, the mean AUC was 0.73 (95 CI: 0.700.76). Conclusions. The present studys findings showed that MRI significantly improved the detection accuracy of prostate cancer and had the highest discrimination to distinguish candidates for biopsy.
- 8 June 2022
- Published by Hindawi Limited in Prostate Cancer
- Vol. 2022, 1-10
Open AccessDiagnostic Accuracy of Predictive Models in Prostate Cancer: A Systematic Review and Meta-Analysis
Aim. Accurate diagnosis of prostate cancer (PCa) has a fundamental role in clinical and patient care. Recent advances in diagnostic testing and marker lead to standardized interpretation and increased prescription by clinicians to improve the detection of clinically significant PCa and select patients who strictly require targeted biopsies. Methods. In this study, we present a systematic review of the overall diagnostic accuracy of each testing panel regarding the panel details. In this meta-analysis, using a structured search, Web of Science and PubMed databases were searched up to 23 September 2019 with no restrictions and filters. The studys outcome was the AUC and 95 confidence interval of prediction models. This index was reported as an overall and based on the WHO region and models with/without MRI. Results. The thirteen final articles included 25,691 people. The overall AUC and 95 CI in thirteen studies were 0.78 and 95 CI: 0.730.82. The weighted average AUC in the countries of the Americas region was 0.73 (95 CI: 0.700.75), and in European countries, it was 0.80 (95 CI: 0.720.88). In four studies with MRI, the average weighted AUC was 0.88 (95 CI: 0.860.90), while in other articles where MRI was not a parameter in the diagnostic model, the mean AUC was 0.73 (95 CI: 0.700.76). Conclusions. The present studys findings showed that MRI significantly improved the detection accuracy of prostate cancer and had the highest discrimination to distinguish candidates for biopsy.